America learned to add medications. Add one for sleep. Add one for nausea from the first. Add one for weight gain from the second. Add a second antidepressant when the first loses effect. Add a stimulant when a mood stabilizer slows a teenager down. Add an antipsychotic when anxiety erupts in the clinic room. Add a statin because a lab number sits outside a guideline range. Patients, however, feel the accumulation and families live with the fallout. Clinicians carry moral injuries. Each refill feels like a promise. Each new prescription feels like rescue. Years pass. Rescue turns into routine. Routine turns into a cage.

Deprescribing offers a different posture. Deprescribing means a planned and supervised reduction or stopping of medication when harm outweighs benefit, aligned with patient goals and values. Psychiatry now uses this language. The word moved from geriatrics into psychopharmacology, and clinicians argue about scope, timing, and safety. Debate signals progress. Silence signals stagnation.

During my NIH years, I learned from Dr. Ezekiel Emanuel as he spoke publicly about declining medical interventions after age 75, including antibiotics and vaccines. Clinicians reacted with anger or admiration. The lesson matters. A thoughtful clinician chooses fewer interventions without choosing abandonment. A clinician honors quality of life and personal values without sliding into neglect.

The Deprescribing America movement started long before headlines. Clinicians started this work at the bedside. Geriatricians faced medication lists longer than family trees. Hospitalists watched delirium follow anticholinergics and benzodiazepines. Primary care clinicians watched older adults fall after blood pressure regimens stacked too high. Pharmacists caught drug interactions before harm reached crisis. Researchers built networks and trials to test structured deprescribing, including federally funded research such as the U.S. Deprescribing Research Network. Evidence also grows in outpatient settings. A 2025 JAMA Network Open analysis linked deprescribing interventions with lower medication counts and fewer potentially inappropriate medications in community-dwelling older adults.

KevinMD writers sounded the alarm years ago. One essay challenged expanding statin prescribing and asked readers to weigh side effects and trade-offs. The cholesterol debate still matters because the statin story mirrors a broader pattern. Guidelines expand. Thresholds drop. Fear rises. More people enter long-term therapy without a plan for reassessment.

I wrote about overmedication in 2025 because I see the same pattern in psychiatry. Too many patients receive psychotropics without an exit plan. Discontinuation syndromes and withdrawal masquerade as relapse. Clinicians misread withdrawal as illness and add medication. Patients lose trust in their bodies. In my clinic, I hear the same sentence again and again: Nobody told me how to stop.

Now federal policy adds momentum. The president’s Make America Healthy Again Commission directs a review of potential overutilization of medication, with emphasis on prescribing of SSRIs, antipsychotics, mood stabilizers, stimulants, and weight loss drugs, with an explicit focus on children. This mandate moves deprescribing into national strategy. Clinicians should treat this moment as a quality initiative, not a culture war. Measure prescriptions, side effects, and function. Report taper outcomes. Learn from failures. Share protocols. Build teams with pharmacists and therapists. Protect time for follow-up.

Psychiatry feels the tremor. Professional organizations urged stepwise deprescribing with attention to individual risk, context, and relapse hazards. The Journal of Clinical Psychiatry also pressed the field to define deprescribing clearly and to reclaim the term from misuse. The term entered the medical lexicon in 2003. Psychiatry now has to build definitions, training, and shared standards.

Deprescribing in youth demands rigor.

Deprescribing in youth demands rigor. Children grow and brains develop. Families hold fear. Schools hold expectations. The prescriber defines the target symptom, the functional goal, and the timeline. The prescriber measures sleep, appetite, school function, irritability, suicidality, and substance use. The prescriber builds nondrug supports before dose reduction, including therapy, sleep routines, exercise, family work, and school coordination.

Start with a medication ma.p

Start with a medication map. Each drug needs an indication in plain words, a start date, and a response history. Each drug needs a side effect inventory, including weight, blood pressure, glucose, cognition, and emotional blunting. Then choose a single priority. Reduce the highest risk drug first. Taper slowly with scheduled follow-up and a clear rescue plan. Recheck the original diagnosis after each taper step. Many labels soften once medications stop fighting each other.

Deprescribing also needs a trauma lens.

Deprescribing also needs a trauma lens. Many patients carry dismissal, stigma, and coercion in prior care. A taper demands trust. Trust grows through shared decisions, predictable follow-up, and honest education about withdrawal and rebound symptoms. Some voices fold vaccines into the deprescribing conversation. Vaccines do not match the category of daily chronic medications, yet public trust in medicine touches both. Public debate intensified after the CDC adopted individual-based decision-making for hepatitis B vaccination timing for infants born to mothers who test negative. The CDC suggested beginning the series no earlier than two months when parents defer the birth dose. The American Academy of Pediatrics maintained a recommendation for a hepatitis B birth dose within 24 hours. Clinicians should protect shared decision-making while keeping prevention, safety, and clear documentation at the center of care.

Deprescribing demands a culture shift.

Deprescribing demands a culture shift. Clinicians need permission to stop. Patients need permission to ask. Health systems need incentives aligned with outcomes, not volume. Payment should reward medication reconciliation, adverse event reduction, and patient-reported function. Insurers should pay for the time taper work requires. Deprescribing also demands moral clarity. Deprescribing does not mean denial of care. Deprescribing does not mean moral superiority. Deprescribing does not mean war on medication. Many medications save lives. Many medications restore function. A person with schizophrenia who thrives on a stable antipsychotic deserves stability and dignity. A child with severe ADHD who regains school success with a stimulant deserves careful monitoring and continuity.

You lead this movement one chart at a time. You ask why medication started. You ask what has changed since the start date. You ask what outcome the patient wants next. You build a taper plan with milestones. You write the plan in plain language. You schedule follow-up. You set guardrails for safety.

America does not need a purge. America needs an upgrade. Deprescribing offers a disciplined way to reduce harm, restore agency, and rebuild trust. The work starts in the room with you and your patient.

Muhamad Aly Rifai is a nationally recognized psychiatrist, internist, and addiction medicine specialist based in the Greater Lehigh Valley, Pennsylvania. He is the founder, CEO, and chief medical officer of Blue Mountain Psychiatry, a leading multidisciplinary practice known for innovative approaches to mental health, addiction treatment, and integrated care. Dr. Rifai currently holds the prestigious Lehigh Valley Endowed Chair of Addiction Medicine, reflecting his leadership in advancing evidence-based treatments for substance use disorders.

Board-certified in psychiatry, internal medicine, addiction medicine, and consultation-liaison (psychosomatic) psychiatry, Dr. Rifai is a fellow of the American College of Physicians (FACP), the American Psychiatric Association (FAPA), and the Academy of Consultation-Liaison Psychiatry (FACLP). He is also a former president of the Lehigh Valley Psychiatric Society, where he championed access to community-based psychiatric care and physician advocacy.

A thought leader in telepsychiatry, ketamine treatment, and the intersection of medicine and mental health, Dr. Rifai frequently writes and speaks on physician justice, federal health care policy, and the ethical use of digital psychiatry.

You can learn more about Dr. Rifai through his Wikipedia page, connect with him on LinkedIn, X (formerly Twitter), Facebook, or subscribe to his YouTube channel. His podcast, The Virtual Psychiatrist, offers deeper insights into topics at the intersection of mental health and medicine. Explore all of Dr. Rifai’s platforms and resources via his Linktree.